Chemicals

Demand improving in specific segments

In 3QFY25, most chemical companies under our coverage are likely to witness sales recovery YoY; Archean will be the only outlier. For SRF, fluoro specialty chemicals sales could see an uptick given likely pick-up of existing products. For PI, CSM sales are likely to see YoY growth owing to decent demand of Pyroxa along with some pick-up in new products. For Deepak, sequential uptick in phenolic spreads is likely to lift the performance of the phenolics business while the standalone business is likely to improve. Higher industrial salt volumes will bode well for Archean. Clean Science will benefit from volume pick-up of HALS along with other new products. PCBL's carbon black volumes are likely to decline sequentially. However, higher EBIT contribution from Aquapharm will partly offset this negative impact. Ami will benefit from ramp-up of CDMO sales. Sharp jump in vegetable oil and derivatives prices will bode well for the spreads of Galaxy Surfactants. On the agrochemicals front, generic agrochemicals are likely to see decent uptick while marginal recovery has been seen in patches for nongeneric agrochemicals.

- SRF's EBITDA likely to grow 6% YoY: SRF's 3QFY25 EBITDA is likely to be up 6% YoY on account of improved performance in the chemicals business, owing to recovery in the specialty chemicals business. Chemicals sales are likely to be up 3% YoY. Further, owing to positive operating leverage, we expect chemicals EBIT margin to come in at 19% (vs. 18.1% in 2QFY25).
- PI's EBITDA likely to shrink 8% YoY: For PI, CSM revenue is likely to be up 6% YoY while the domestic business is likely to be up 5% YoY. Besides, PI's pharma business could see some sequential recovery. Moreover, there will be sales contribution from the recently acquired plant health care business. As a result, its 3QFY25 revenue is likely to increase 2%YoY. We have assumed EBITDA margin at 26.2% (vs. 28%/29% in 2QFY25/3QFY24). As a result, EBITDA is likely to be down 8%/19% YoY/QoQ.
- Fine Organics' EBITDA to shrink 16% QoQ and Tatva Chintan's EBITDA to grow 36% sequentially: We estimate Fine's 3QFY25 sales to be drop 11% sequentially, largely on account of slowdown in volume offtake. Further, owing to negative operating leverage, Fine's EBITDA is likely to contract 16% QoQ. For Tatva, we estimate 7% sequential sales increase on account of sales recovery across segments. Further, we expect sequential 186bps EBITDA margin jump. As a result, Tatva's EBITDA is likely to jump 36% QoQ (still down 31% YoY).
- Anupam Rasayan's EBITDA to grow 13% YoY; PCBL's EBITDA to shrink 6% QoQ: We estimate Anupam Rasayan's 3QFY25 sales to grow 10% YoY while EBITDA margin could be up 74bps YoY on account of positive operating leverage. As a result, Anupam's EBITDA is likely to grow 13% YoY. For PCBL, we expect 3% sequential drop in sales owing to slowdown in carbon black offtake. Further, owing to 40bps sequential EBITDA margin decline, we expect PCBL's EBITDA to be down 6% QoQ (still up 23% YoY).
- Clean Science's EBITDA to grow by 1% QoQ; Galaxy's EBITDA to jump 6% QoQ: We estimate Clean's 3QFY25 revenue to grow by 3% QoQ on account of ramp-up of new products. Further, on account of slightly lower EBITDA margin, EBITDA is likely to grow by 1% QoQ. For Galaxy Surfactants, we have assumed ~4% QoQ jump in sales and jump in EBITDA margin to INR 19,583 per tonne (vs. INR 18,816 per tonne in 2QFY25). This is likely to result in EBITDA jumping by 6% QoQ.
- Deepak's EBITDA to grow by 8% QoQ; Archean's EBITDA to grow by 30% QoQ: During 3QFY25, Deepak's advanced intermediates (AI) sales could rise by 5% sequentially while AI EBIT margin could increase slightly to 9% (vs. 7.8% in 2QFY25). Further, benchmark phenol-acetone spreads during the quarter grew by >3% QoQ. This should result in 8% sequential rise in EBITDA for Deepak Nitrite. Archean's 2QFY25 sales is likely to grow by



Krishan Parwani krishan.parwani@jmfl.com | Tel: (91 22) 6630 3073 Siddhinathan KN siddhinathan.kn@jmfl.com | Tel: (91 22) 6630 3048

JM Financial Research is also available on: Bloomberg - JMFR <GO>, Thomson Publisher & Reuters, S&P Capital IQ, FactSet and Visible Alpha

Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification. 18% QoQ on account of higher salt and slight increase in bromine sales. Further, EBITDA margin is expected to be higher QoQ. As a result, its EBITDA is likely to grow by 30% QoQ.

EBITDA to grow 13% QoQ for Ami: For Ami, we estimate 6% QoQ increase in sales (in 3QFY25) mainly on account of jump in CDMO sales. Further, we expect sequential 124bps EBITDA margin jump owing to higher CDMO contribution. As a result, Ami's EBITDA is likely to jump 13% QoQ.


xhibit 1: Detailed 3QFY25 Estimates									
	3QFY25E	3QFY24	2QFY25	YoY (%)	QoQ (%)				
SRF									
Sales (INR mn)	36,069	30,530	34,243	18.1	5.3				
EBITDA (INR mn)	6,198	5,839	5,606	6.1	10.6				
EBITDA margin (%)	17.2	19.1	16.4	-194 bps	81 bps				
PBT (INR mn)	3,318	3,483	2,837	-4.7	17.0				
PAT (INR mn)	2,422	2,534	2,014	-4.4	20.3				
PI Industries									
Sales (INR mn)	19,437	18,975	22,210	2.4	-12.5				
EBITDA (INR mn)	5,099	5,536	6,282	-7.9	-18.8				
EBITDA margin (%)	26.2	29.2	28.3	-294 bps	-205 bps				
PBT (INR mn)	5,199	5,258	6,628	-1.1	-21.6				
PAT (INR mn)	4,003	4,486	5,082	-10.8	-21.2				
Deepak Nitrite									
Sales (INR mn)	20,852	20,092	20,320	3.8	2.6				
EBITDA (INR mn)	3,212	3,047	2,975	5.4	8.0				
EBITDA margin (%)	15.4	15.2	14.6	24 bps	76 bps				
PBT (INR mn)	2,897	2,736	2,640	5.9	9.7				
PAT (INR mn)	2,155	2,020	1,942	6.7	11				
Clean Science									
Sales (INR mn)	2,445	1,947	2,381	25.6	2.7				
EBITDA (INR mn)	906	866	897	4.6	1.1				
EBITDA margin (%)	37.1	44.5	37.7	-741 bps	-60 bps				
PBT (INR mn)	910	830	832	9.6	9.4				
PAT (INR mn)	683	626	587	9.0	16.2				
Ami Organics									
Sales (INR mn)	2,615	1,664	2,467	57.1	6.0				
EBITDA (INR mn)	551	265	489	107.8	12.6				
EBITDA margin (%)	21.1	15.9	19.8	513 bps	124 bps				
PBT (INR mn)	519	237	500	118.8	3.7				
PAT (INR mn)	384	178	375	115.4	2.2				

Source: Company, JM Financial


Chemicals


Exhibit 2: Detailed 3QFY25 Es						
	3QFY25E	3QFY24	2QFY25	YoY (%)	QoQ (%)	
Fine Organics						
Sales (INR mn)	5,300	4,258	5,955	24.5	-11.0	
EBITDA (INR mn)	1,203	924	1,429	30.2	-15.8	
EBITDA margin (%)	22.7	21.7	24.0	100 bps	-130 bps	
PBT (INR mn)	1,293	946	1,518	36.6	-14.8	
PAT (INR mn)	957	697	1,131	37.3	-15.4	
Galaxy Surfactants						
Sales (INR mn)	11,046	9,405	10,630	17.4	3.9	
EBITDA (INR mn)	1,355	1,125	1,277	20.5	6.2	
EBITDA margin (%)	12.3	12.0	12.0	31 bps	26 bps	
PBT (INR mn)	1,120	878	1,045	27.5	7.2	
PAT (INR mn)	896	714	847	25.6	5.8	
Anupam Rasayan						
Sales (INR mn)	3,250	2,955	2,939	10.0	10.6	
EBITDA (INR mn)	894	, 791	, 804	13.0	11.2	
EBITDA margin (%)	27.5	26.8	27.3	74 bps	16 bps	
PBT (INR mn)	424	359	340	18.1	24.8	
PAT (INR mn)	314	260	306	20.6	2.6	
Tatva Chintan	514	200	300	20.0	2.0	
Sales (INR mn)	890	842	835	5.7	6.6	
EBITDA (INR mn)	76	110	56	-30.8	36.2	
EBITDA margin (%)	8.6	13.1	6.7	-451 bps	186 bps	
PBT (INR mn)	14	52	-10	-73.1	-238.1	
PAT (INR mn)	11	35	-7	-69.4	-259.3	
PCBL						
Sales (INR mn)	20,895	16,568	21,632	26.1	-3.4	
EBITDA (INR mn)	3,427	2,789	3,635	22.9	-5.7	
EBITDA margin (%)	16.4	16.8	16.8	-43 bps	-40 bps	
PBT (INR mn)	1,457	2,011	1,638	-27.5	-11.0	
PAT (INR mn)	1,093	1,479	1,235	-26.1	-11.5	
Archean Chemicals						
Sales (INR mn)	2,847	4,126	2,405	-31.0	18.4	
EBITDA (INR mn)	971	1,454	747	-33.3	29.9	
EBITDA margin (%)	34.1	35.2	31.1	-116 bps	302 bps	
PBT (INR mn)	846	1,351	630	-37.4	34.3	
PAT (INR mn)	634	1,016	157	-37.6	303.1	

Source: Companies, JM Financial




Source: Company, JM Financial







Source: Company, JM Financial



Source: Company, JM Financial



Source: Company, JM Financial







Exhibit 11: FOIL guarterly gross margin trend (%) ■FY23 ■FY24 FY25E 43.6% 44% 42.9% 41.8% <u>4</u>1.0% 42.2% 41.9% 41.3%| 40.5% 39.1% 38.2% 39% 35.1% 34% 29% 24% Q1 Q2 Q3 Q4


Source: Company, JM Financial

Exhibit 13: Galaxy quarterly gross margin trend (%)



Source: Company, JM Financial





Source: Company, JM Financial







Exhibit 12: FOIL quarterly EBITDA margin trend (%)

Exhibit 14: Galaxy quarterly EBITDA margin trend (%)



Source: Company, JM Financial





Source: Company, JM Financial







Exhibit 21: PCBL quarterly gross margin trend (%)

Exhibit 16: Anupam Rasayan quarterly EBITDA margin trend (%)



Source: Company, JM Financial





Source: Company, JM Financial

Exhibit 22: PCBL quarterly EBITDA margin trend (%)


JM Financial Institutional Securities Limited


FY25E


34.1%

50.8%

30.7%







Source: Company, JM Financial




Exhibit 24: Archean Chemicals quarterly EBITDA margin trend (%)

FY24

43.8%

35.2%

FY23

40.4%

32.9%

31.1%

Source: Company, JM Financial

60%

50%

40%

30%

20%

40.2%

39.2%

33.5%

Exhibit 28: Chemical companies peer valuation																			
Company	Rating	CMP (INR)	TP (INR)		P/I	E (x)			P/	B (x)			EV/EBI	TDA (x)			ROE	:(%)	
				FY24	FY25E	FY26E	FY27E	FY24	FY25E	FY26E	FY27E	FY24	FY25E	FY26E	FY27E	FY24	FY25E	FY26E	FY27E
SRF	BUY	2,307	2,660	51.2	54.8	35.5	27.6	6.0	5.4	4.8	4.1	28.0	26.7	20.3	16.5	12.3	10.4	14.3	16.1
PI Industries	HOLD	3,593	4,275	32.7	32.6	28.9	25.0	6.3	5.2	4.4	3.8	25.2	21.8	18.8	16.0	21.0	17.5	16.6	16.3
Deepak Nitrite	BUY	2,461	3,020	41.4	37.7	29.8	24.4	7.0	6.0	5.0	4.2	29.8	25.4	19.9	16.5	18.2	17.1	18.4	18.9
Clean Science	BUY	1,446	1,845	62.9	54.2	39.7	30.9	12.8	10.4	8.3	6.6	45.3	37.6	28.3	21.6	22.1	21.1	23.2	23.7
Navin Fluorine	BUY	3,470	4,105	75.2	61.7	45.3	35.4	7.2	6.6	5.9	5.2	45.1	36.6	28.2	23.0	10.0	11.2	13.8	15.7
Fine Organics	SELL	4,500	4,035	37.4	32.5	33.0	32.9	7.4	6.2	5.4	4.8	26.7	22.5	21.9	20.8	21.8	20.9	17.6	15.4
Galaxy Surfactants	HOLD	2,496	2,810	29.4	25.9	23.9	22.2	4.1	3.5	3.1	2.7	18.5	16.1	14.7	13.4	14.8	14.6	13.8	13.1
PCBL Ltd.	BUY	438	620	33.6	30.8	21.6	16.3	5.1	4.4	3.6	3.0	20.2	14.1	11.8	9.9	16.2	15.2	18.3	20.0
Aether Industries	BUY	894	1,135	123.5	69.6	46.8	35.4	5.8	5.3	4.8	4.2	87.0	46.6	32.4	23.7	5.8	8.0	10.8	12.7
Ami Organics	BUY	2,218	2,500	112.4	72.6	42.5	31.1	13.5	7.1	6.2	5.2	72.0	46.1	28.6	21.2	12.7	12.8	15.5	18.2
Anupam Rasayan	HOLD	710	740	60.6	81.3	46.4	28.9	2.8	2.7	2.5	2.3	22.9	26.3	19.1	14.7	5.0	3.4	5.7	8.4
Archean Chemicals	BUY	652	795	24.8	28.5	19.7	12.9	4.7	4.2	3.5	2.8	16.4	19.0	12.3	7.9	20.4	15.4	19.3	23.9
Tatva Chintan Pharma Chem	SELL	900	705	69.3	147.1	63.2	38.3	2.9	2.8	2.7	2.6	30.5	46.1	27.7	19.7	4.8	1.9	4.4	6.9

Source: Companies, JM Financial

		Sales (INR bn)		Sales CAGR (%)	EBITDA CAGR (%)		Pat (I	PAT CAGR (%)						
Company	FY24	FY25E	FY26E	FY27E	FY24 - FY27E	FY24	FY25E	FY26E	FY27E	FY24 - FY27E	FY24	FY25E	FY26E	FY27E	FY24 - FY27E
Anupam Rasayan	14.8	13.8	17.2	21.5	13.5	3.8	3.4	4.6	6.0	16.4	1.7	1.4	2.1	3.2	23.8
Clean Science Tech	7.9	9.9	14.1	18.2	32.1	3.3	4.0	5.2	6.7	26.6	2.4	2.8	3.9	5.0	26.8
Tatva Chintan	3.9	3.8	4.8	5.9	14.3	0.7	0.5	0.8	1.1	16.8	0.3	0.1	0.3	0.6	21.9
Galaxy Surfactants	37.9	40.7	43.6	46.5	7.0	4.6	5.2	5.5	5.8	8.0	3.0	3.4	3.7	4.0	9.8
PI Industries	76.7	82.1	93.7	106.8	11.7	20.1	23.1	26.3	29.9	14.1	16.7	16.7	18.9	21.8	9.3
SRF Ltd	129.1	149.6	174.3	202.5	16.2	25.8	27.1	35.4	43.2	18.7	13.4	12.5	19.3	24.8	22.9
Deepak Nitrite	76.8	83.1	93.9	102.4	10.0	11.2	13.2	16.8	20.3	21.8	8.1	8.9	11.3	11.3	11.6
Fine Organics	19.5	23.4	24.6	25.8	9.8	4.8	5.6	5.7	5.9	7.3	3.7	4.2	4.2	4.2	4.4
PCBL	64.2	86.3	100.3	113.7	21.0	10.4	14.9	17.6	20.5	25.4	4.9	5.4	7.6	10.1	27.3
Archean Chemical	13.3	12.0	17.9	24.4	22.4	4.6	4.0	5.9	8.7	23.5	3.2	2.4	4.0	6.1	24.2
Ami Organics	7.2	9.8	13.1	16.7	32.4	1.3	2.0	3.1	4.2	48.3	0.5	1.3	2.1	2.9	81.7

Source: Companies, JM Financial

APPENDIX I

JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.com

Compliance Officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1073 | Email: sahil.salastekar@jmfl.com

Grievance officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1073 | Email: instcompliance@jmfl.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Definition of ratings								
Rating	Meaning							
Buy	Total expected returns of more than 10% for stocks with market capitalisation in excess of INR 200 billion and REITs* and more than 15% for all other stocks, over the next twelve months. Total expected return includes dividend yields.							
Hold	Price expected to move in the range of 10% downside to 10% upside from the current market price for stocks with market capitalisation in excess of INR 200 billion and REITs* and in the range of 10% downside to 15% upside from the current market price for all other stocks, over the next twelve months.							
Sell	Price expected to move downwards by more than 10% from the current market price over the next twelve months.							

* REITs refers to Real Estate Investment Trusts.

Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., <u>JM Financial Institutional Securities has an affiliate</u>, JM Financial Securities, Inc. located at 1325 Avenue of the Americas, 28th Floor, Office No. 2821, <u>New York, New York 10019</u>. Telephone +1 (332) 900 4958 which is registered with the SEC and is a member of FINRA and SIPC.

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions and a "permitted client" as such term is defined in National Instrument 45-106 Prospectus Exemptions. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or